Search

everythinglearnresearchcommunity

for

Search:↓

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

The treatment was ineffective in humans.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Aumolertinib effectively controls lung cancer and improves quality of life.

Glibenclamide slows breast cancer cell growth by stopping cell division.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Erlotinib can cause hair loss as a side effect.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Ivarmacitinib effectively regrows hair in severe alopecia areata.